With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed ...
GlobalData on MSN
GSK acquires RAPT Therapeutics for $2.2bn
The acquisition will strengthen GSK’s immunology pipeline, which is a key area of focus for the pharma company.
Pharmaceutical Technology on MSN
JPM26: GSK banks on recent AI deals to offset patent expiries
GSK noted recent deals as source of fresh revenues amid patent expiries and an AI-driven boost to drug discovery.
South Korean biotech Alteogen (Kosdaq: 196170) has signed an exclusive license agreement with Tesaro, a unit of GSK (LSE: GSK ...
Noetik, an AI-native biotech company developing self-supervised machine learning and high-throughput spatial data to develop cancer therapeutics, has announced a five-year strategic collaboration and ...
Alteogen has signed a licensing agreement with Tesaro, a subsidiary of global pharmaceutical powerhouse GSK, for the ...
China NMPA approves GSK’s Trelegy Ellipta for use in adults with uncontrolled asthma: London, UK Saturday, January 24, 2026, 09:00 Hrs [IST] GSK plc announced that China’s Nat ...
Alteogen Inc. (KOSDAQ: 196170) announced today that the company has entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of GSK. Under the terms of the agreement, Tesaro will ...
GSK Plc (NYSE:GSK) has filed a lawsuit against Moderna, Inc. (NASDAQ:MRNA) and its affiliates, alleging that Moderna’s mRNA vaccines infringe on patents developed by GSK. According to GSK, the ...
GlaxoSmithKline has made a hire signaling its commitment to digital health. Karenann Terrell, former Chief Information Officer at Walmart, will start at GSK in the newly created role of Chief Digital ...
Settlement reached over mRNA-based COVID vaccines CureVac and GSK get $740 million upfront, and royalties BioNTech's deal to buy CureVac on track GSK's own lawsuits against Pfizer, BioNTech unaffected ...
Alteogen Announces Exclusive License Agreement With Tesaro, A Subsidiary Of GSK, For The Development Of A Subcutaneous Formulation Of Dostarlimab Enabled By Hybrozymetm Technology. DAEJEON, South ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results